Skip to main content
SpringerLink
Log in

Systemic Adverse Effects of Topical Ophthalmic Agents

Implications for Older Patients

  • Review Article
  • Adverse Effects
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Topical ophthalmic medications are widely prescribed by growing numbers of eye-care professionals. Increasingly, these agents are being prescribed by optometrists and ophthalmic-trained nurses in addition to ophthalmologists and general practitioners. As the number and variety of topical agents on the market rises, and as the number of clinicians involved in prescribing those agents increases, the risk of systemic adverse effects will also increase. Thus, professionals involved in the care of these patients must be aware of the risks associated with these drugs in order to minimise the likelihood of complications. Moreover, inadequate training may result in the clinician failing to associate a topical medication with a systemic condition, allowing an adverse effect to pass unrecognised. It is therefore in the interest of the ophthalmic and pharmaceutical communities to improve awareness of the potential dangers intrinsic in the use of topical eye medications.

It is the elderly population who are at greatest risk of experiencing systemic adverse effects of topical agents. Chronic ophthalmic diseases, and hence long term ophthalmic drop treatments, are more prevalent among older people. Such individuals are also likely to have other medical conditions (e.g. cardiac, respiratory or neurological disease) that may be induced or exacerbated by topical ophthalmic agents. Moreover, polypharmacy is common in elderly people, and this is associated with an increased risk of drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fraunfelder FT, Meyer SM. Safe use of ocular drugs in the elderly. Geriatrics 1984; 39: 97–102

    PubMed  CAS  Google Scholar 

  2. Barber BL, Santanello NC. Relating spontaneous adverse experience reports to scores on a questionnaire querying tolerability. Int J Clin Pharmacol Ther 1995; 33: 598–604

    PubMed  CAS  Google Scholar 

  3. Mishima A. Some physiologic aspects of the pre-corneal tear film. Arch Ophthalmol 1965; 73: 233–41

    Article  PubMed  CAS  Google Scholar 

  4. Maurice DM. The dynamics and drainage of tears. Int Ophthalmol Clin 1973; 13: 103–16

    Article  PubMed  CAS  Google Scholar 

  5. Chrai SS, Robinson JR. Ocular evaluation of methylcellulose vehicle in albino rabbits. J Pharm Sci 1974; 63: 1218–23

    Article  PubMed  CAS  Google Scholar 

  6. Patton TF, Robinson JR. Ocular evaluation of polyvinyl-alcohol in rabbits. J Pharm Sci 1975; 64: 1312–6

    Article  PubMed  CAS  Google Scholar 

  7. Zimmerman TJ, Kooner KS, Kandarakis AS, et al. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984; 102: 551–3

    Article  PubMed  CAS  Google Scholar 

  8. Huang TC, Lee DA. Punctal occlusion and topical medications for glaucoma. Am J Ophthalmol 1989; 107: 151–5

    PubMed  CAS  Google Scholar 

  9. Chrai SS, Makoid MC, Ericksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974; 63: 333–8

    Article  PubMed  CAS  Google Scholar 

  10. Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 1986; 2: 67–108

    Article  PubMed  CAS  Google Scholar 

  11. Gundert-Remy U. Alter als faktor der dosis-wirkungs beziehung von arzneimitteln. Z Gerontol Geriatr 1995; 28: 408–14

    PubMed  CAS  Google Scholar 

  12. Solosko D, Smith RB. Hypertension following 10% phenylephrine ophthalmic. Anaesthesiology 1972; 36: 187–9

    Article  CAS  Google Scholar 

  13. Heath P, Geiter CW. Use of phenylephrine hydrochloride (Neo-Synephine hydrochloride) in ophthalmology. Arch Ophthalmol 1940; 41: 172–7

    Article  Google Scholar 

  14. McReynolds WU, Havener WH, Henderson JW. Hazards of the use of sympathomimetic drugs in ophthalmology. Arch Ophthalmol 1956; 56: 176–9

    Article  Google Scholar 

  15. Meyer SM, Fraunfelder FT. Phenylephrine hydrochloride. Ophthalmology 1980; 87: 1177–80

    PubMed  CAS  Google Scholar 

  16. Wilensky J, Woodward H. Acute systemic hypertension after conjunctival instillation of phenylephrine hydrochloride. Am J Ophthalmol 1973; 76: 156–7

    PubMed  CAS  Google Scholar 

  17. Lai YK. Adverse effect of intraoperative phenylephrine 10%: case report. Br J Ophthalmol 1989; 73: 468–9

    Article  PubMed  CAS  Google Scholar 

  18. Fraunfelder FT, Meyer SM. Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine [letter]. Am J Ophthalmol 1985; 99: 362–3

    PubMed  CAS  Google Scholar 

  19. Lanche R. Systemic reactions to topical epinephrine and phenylephrine. Am J Ophthalmol 1966; 61: 95–8

    Google Scholar 

  20. McReynolds W, Havener W, Henderson J. Hazards of the use of sympathomimetic drugs in ophthalmology. Arch Ophthalmol 1956; 56: 176–9

    Article  Google Scholar 

  21. Leopold IH. The phenylephrine saga — a drug dilemma. Am J Ophthalmol 1978; 85: 572–4

    PubMed  CAS  Google Scholar 

  22. Smith SA. Factors determining the potency of mydriatic drugs in man. Br J Clin Pharmacol 1976; 3: 503–7

    Article  PubMed  CAS  Google Scholar 

  23. Tyson WJ. Toxic effects of atropine drops. BMJ 1889; II: 921

    Google Scholar 

  24. Heath WE. Death from atropine poisoning. BMJ 1950; II: 68

    Google Scholar 

  25. Beswick JA. Psychosis from cyclopentolate. Am J Ophthalmol 1962; 53: 879–80

    Google Scholar 

  26. Praeger DL, Miller SN. Toxic effects of cyclopentolate (Cyclo-gel). Am J Ophthalmol 1964; 58: 1060

    PubMed  CAS  Google Scholar 

  27. Simcoe CW. Cyclopentolate (Cyclogyl) toxicity. Arch Ophthalmol 1962; 67: 406–8

    Article  PubMed  CAS  Google Scholar 

  28. Binkhorst RD, Weinstein GW, Baretz RM, et al. Psychotic reaction induced by cyclopentolate (Cyclogyl). Am J Ophthalmol 1963; 55: 1243–5

    PubMed  CAS  Google Scholar 

  29. Mark HH. Psychotogenic properties of cyclopentolate. JAMA 1963; 186: 430–1

    Article  PubMed  CAS  Google Scholar 

  30. Falbe WJ, Boyd DL. Homatropine-associated confusion in an elderly patient [letter]. J Am Geriatr Soc 1988; 36: 649

    PubMed  CAS  Google Scholar 

  31. Delberghe X, Zegers de Beyl D. Repeated delirium from hom-atropine eye drops: a case report. Clin Neurol Neurosurg 1987; 89: 53–4

    Article  PubMed  CAS  Google Scholar 

  32. Kennerdell JS, Wucher FP. Cyclopentolate associated with two cases of grand mal seizure. Arch Ophthalmol 1972; 87: 634–5

    Article  PubMed  CAS  Google Scholar 

  33. Carpenter WT. Precipitous mental deterioration following cycloplegia with 0.2% cyclopentolate HCl. Arch Ophthalmol 1967; 78: 445–7

    Article  PubMed  Google Scholar 

  34. Rich ML, Ritterhoff RJ, Hoffman RJ. A fatal case of aplastic anaemia following chloramphenicol therapy. Ann Intern Med 1950; 33: 1459–67

    PubMed  CAS  Google Scholar 

  35. Fraunfelder FT, Grover GC, Kelly DJ. Fatal aplastic anaemia following topical application of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 92: 356–60

    Google Scholar 

  36. Fraunfelder FT, Morgan RL, Yunis AA. Blood dyscrasias and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993; 115: 812–3

    PubMed  CAS  Google Scholar 

  37. Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: time to cry halt? BMJ 1995; 310: 1217–8

    Article  PubMed  CAS  Google Scholar 

  38. Diamond JP, Leeming JP. Chloramphenicol eye drops: a dangerous drug? Practitioner 1995; 239: 608–11

    PubMed  CAS  Google Scholar 

  39. Mulla RJ, Barnes B, Rogers TR. Is it time to stop using chloramphenicol on the eye? Fears are based on only 6 cases [letter]. BMJ 1995; 311: 450

    Article  PubMed  CAS  Google Scholar 

  40. Buckley RJK, Kirkness CM, Kanski JJ, et al. Is it time to stop using chloramphenicol on the eye? Safe in patients with no history of blood dyscrasia [letter]. BMJ 1995; 311: 450

    Article  PubMed  CAS  Google Scholar 

  41. Fraunfelder FT, Bagby GC. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 93: 356–60

    PubMed  CAS  Google Scholar 

  42. Kini MM, Leibowitz HM, Colton T, et al. Prevalence of senile cataract, diabetic retinopathy, senile macular degeneration, and open-angle glaucoma in the Framingham eye study. Am J Ophthalmol 1978; 85: 28–34

    PubMed  CAS  Google Scholar 

  43. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980; 87: 447–50

    PubMed  Google Scholar 

  44. Williams T, Gither WH. Hazards of ophthalmic timolol. N Engl J Med 1982; 306: 1485–6

    Article  PubMed  CAS  Google Scholar 

  45. Affrime MB, Lowenthal DT, Tobert JA, et al. Dynamics and kinetics of ophthalmic timolol. Clin Pharmacol Ther 1980; 27: 471–7

    Article  PubMed  CAS  Google Scholar 

  46. Diggory P, Cassels-Brown A, Vail A, et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardio-selective or sympathomimetic agents. Lancet 1995; 345: 1604–6

    Article  PubMed  CAS  Google Scholar 

  47. Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitics. Am J Ophthalmol 1984; 97: 86–92

    PubMed  CAS  Google Scholar 

  48. Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986. Am J Ophthalmol 1987; 103: 592

    PubMed  CAS  Google Scholar 

  49. Brooks AMV, Gillies WE. Ocular beta-blockers in glaucoma management. Drugs Aging 1992; 2: 208–21

    Article  PubMed  CAS  Google Scholar 

  50. Dunn TL, Gerber MJ, Shen AS, et al. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis 1986; 133: 264–8

    PubMed  CAS  Google Scholar 

  51. Sonntag JR, Brindley GO, Sheilds MB, et al. Timolol and epinephrine: comparison of efficacy and side-effects. Arch Ophthalmol 1979; 97: 273–7

    Article  PubMed  CAS  Google Scholar 

  52. Horie T, Takahashi O, Shirato S, et al. Comparison of ocular hypotensive effects of topical timolol and Carteolol. Jpn J Clin Pharm 1982; 36: 1065–70

    Google Scholar 

  53. Linkewich JA, Herling IM. Bradycardia and congestive cardiac failure associated with ocular timolol maleate. Am J Hosp Pharm 1981; 38: 699–701

    PubMed  CAS  Google Scholar 

  54. Backlund M, Kirvela M, Lindgren L. Cardiac failure aggravated by timolol eye drops: preoperative improvement by changing to pilocarpine. Acta Anaesthesiol Scand 1996; 40: 379–81

    Article  PubMed  CAS  Google Scholar 

  55. Leier CV, Baker ND, Weber PA. Cardiovascular effects of ophthalmic timolol. Ann Intern Med 1986; 104: 197–9

    PubMed  CAS  Google Scholar 

  56. Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiac events attributed to Timoptol eye solution, 1978–1985. Am J Ophthalmol 1986; 102: 606–11

    PubMed  CAS  Google Scholar 

  57. McMahon CD, Shaffer RN, Hoskins HD, et al. Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979; 88: 736–8

    PubMed  CAS  Google Scholar 

  58. Atkins JM, Pugh Jr BR, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol 1985; 99: 173–5

    PubMed  CAS  Google Scholar 

  59. Vahidasser MD, Foy CJ, O’Malley T, et al. Eye drops and lethargy. J R Soc Med 1997; 90: 155

    Google Scholar 

  60. Goldberg I, Goldberg H. Betaxolol eye drops — a clinical trial of safety and efficacy. Aust N Z J Ophthalmol 1995; 23: 17–24

    Article  PubMed  CAS  Google Scholar 

  61. DeSantis L, Chandler M. Cardiac beta blockade after ocular instillation of beta adrenergic blockers in alert cynomolgus monkeys: safety profile for betaxolol [abstract]. Invest Ophthalmol Vis Sci 1985; 26: 227

    Google Scholar 

  62. Le Jeunne CL, Hughes FC, Dufier JL, et al. Bronchial and cardiovascular effects of ocular topical β-antagonists in asthmatic subjects: comparison of timolol, Carteolol and metipranolol. J Clin Pharmacol 1989; 29: 97–101

    PubMed  Google Scholar 

  63. Duch S, Duch C, Pasto L, et al. Changes in depressive status associated with topical beta-blockers. Int Ophthalmol 1992; 16: 331–5

    Article  PubMed  CAS  Google Scholar 

  64. Fraunfelder FT, Meyer SM. Sexual dysfunction secondary to topical ophthalmic timolol. JAMA 1985; 253: 3092–3

    Article  PubMed  CAS  Google Scholar 

  65. Zimmerman TJ, Baumann JD, Hetherington J. Side effects of timolol. Surv Ophthalmol 1983; 28: 243–9

    Article  PubMed  Google Scholar 

  66. Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker. J Clin Psychopharmacol 1987; 7: 264–7

    Article  PubMed  CAS  Google Scholar 

  67. Orlando RG. Clinical depression associated with betaxolol. Am J Ophthalmol 1986; 102: 275

    Article  PubMed  CAS  Google Scholar 

  68. Dinai Y, Sharir M, Naveh N, et al. Bradycardia induced by interaction between quinidine and ophthalmic timolol. Ann Intern Med 1985; 103: 890–1

    PubMed  CAS  Google Scholar 

  69. Glynn RJ, Seddon JM, Krug Jr JH, et al. Falls in elderly patients with glaucoma. Arch Ophthalmol 1991; 109: 205–10

    Article  PubMed  CAS  Google Scholar 

  70. Ellis PP. Systemic reactions to topical therapy. Int Ophthalmol Clin 1971; 11: 1–11

    Article  PubMed  CAS  Google Scholar 

  71. Greco JJ, Kelman CD. Systemic pilocarpine toxicity in the treatment of angle-closure glaucoma. Ann Ophthalmol 1973; 5: 57–9

    PubMed  CAS  Google Scholar 

  72. Littmann L, Kempler P, Rohla M, et al. Severe symptomatic atrioventricular block induced by pilocarpine eye drops. Arch Intern Med 1987; 147: 586–7

    Article  PubMed  CAS  Google Scholar 

  73. Ballin N, Becker B, Goldman M. Systemic side effects of epinephrine applied topically to the eye. Invest Ophthalmol Vis Sci 1966; 5: 125–9

    CAS  Google Scholar 

  74. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Ann Intern Med 1990; 112: 120–5

    PubMed  CAS  Google Scholar 

  75. Abrams DA, Robin AL, Pollack IP, et al. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol 1987; 105: 1205–7

    Article  PubMed  CAS  Google Scholar 

  76. Stewart WC, Laibovitz R, Horwitz B, et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Arch Ophthalmol 1996; 114: 938–42

    Article  PubMed  CAS  Google Scholar 

  77. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response and dosing studies. Surv Ophthalmol 1996; 41 Suppl.: 19–26

    Article  Google Scholar 

  78. O’Day DM, McKenna TJ, Elliot JH. Ocular corticosteroid therapy: systemic hormonal effects. Trans Am Acad Ophthalmol Otolaryngol 1975; 79: 71–7

    Google Scholar 

  79. Romano PE, Traisman HS, Green OC. Fluorinated corticosteroid toxicity in infants. Am J Ophthalmol 1977; 84: 247–50

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Directorate of Ophthalmology, Bristol Eye Hospital, Bristol, England

    Jeremy P. Diamond

Authors
  1. Jeremy P. Diamond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeremy P. Diamond.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diamond, J.P. Systemic Adverse Effects of Topical Ophthalmic Agents. Drugs & Aging 11, 352–360 (1997). https://doi.org/10.2165/00002512-199711050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199711050-00003

Keywords

Search

Navigation